New advisory board member

Panion Animal Health AB develops a gene therapy product for treatment of epilepsy in dogs, for which the clinical phase has started.

Panion's highly competent advisory board has now been expanded with the fourth member, Dr. Dominic J. Marino, DVM, DACVS, DACCT, CCRP, who is the lead investigator of the ongoing clinical study in dogs.

Dr. Dominic J. Marino is an experienced veterinary neurologist and neurosurgeon He is the Chief of Staff of Long Island Veterinary Specialists, the Director of the Canine Chiari Institute, and a founding board member of the New York Veterinary Foundation. Dr. Marino pursued his life-long animal passion by attending Auburn University in Alabama where he attained a B.S. in biology and a DVM degree. Dr. Marino is board certified by the American College of Veterinary Surgeons and the American College of Clinical Thermology and is the former head of Orthopedic/Neurosurgery service at the Animal Medical Center. Fulfilling his desire to make cutting-edge veterinary medicine available to the pets of Long Island, he joined with Drs. Kaplan, Sapienza, and Panich to start Island Veterinary Referral which later evolved into Long Island Veterinary Specialists.

Dr. Marino has published many scientific articles, and authored chapters in both human and veterinary medical textbooks. He lectures extensively on many surgical topics including soft tissue, orthopedic and neurosurgery at both human and veterinary surgical conferences nationally and internationally. Dr. Marino has participated in collaborative research projects with several institutions including Stonybrook Medical School and Brookhaven National Laboratory on Long Island.

Dr. Marino served as the surgical consultant to Nassau University Medical Center, East Meadow, NY, chairman of the Eastern Veterinary Orthopedic Society, and on the National Advisory Board of North Shore Animal League of America. He is currently an executive board member of the New York Veterinary Foundation, The Police Surgeons Benevolent Association and the medical advisory board of the CSF foundation.

"We are very pleased that Dr. Marino makes his expertise available for Panion's epilepsy project in dogs. As a true expert in the field, his advice and guidance will be of tremendous benefit to us" says Anja Holm, CEO of Panion.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

Information avseende budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löpte ut den 20 juni (-19).


Påminnelse angående budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löper ut den 20 juni (-19).





2019 Q1 report, Period January-March for Panion Animal Health AB

Period January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 663 (-697).
  • Earnings per share: SEK -0,07 (-0,05).
  • Liquidity at the end of the period: kSEK 4 961 (2 708).

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande


Kommuniké från årsstämma i Panion Animal Health AB (publ)

Idag, den 23 april 2019, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.


CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").



Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär